Stocktoria
Nexalin Technology, Inc. NXL
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2022-09-16
Nexalin Technology, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 79.7% | 78.3% | 76.8% | 72.5% | 85.1% |
| Operating margin | -2781.7% | -4596.1% | -5143.5% | -138.7% | -4177.7% |
| Net margin | -2725.8% | -4508.7% | -4197.6% | -128.5% | -4218.9% |
| Return on assets | -177.4% | -180.1% | -128.0% | -22.8% | -806.4% |
| Return on equity | -219.4% | -206.9% | -145.0% | -31.0% | 361.4% |
| Current ratio | 4.85 | 7.25 | 8.07 | 3.81 | 0.32 |
| Revenue growth | 78.8% | 52.3% | -91.6% | 817.2% | — |
Source: SEC EDGAR filings · CIK 0001527352 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.